...for the fiscal year ended March 31. The deal is expected to close in 4Q15. R-Tech Ueno Ltd....

...Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) launched a tender offer to acquire R-Tech Ueno Ltd. (JASDAQ:4573) for Y33 billion ($273.9...

...under the deal and said it plans to license the compound following a proof-of-concept study. R-Tech Ueno...

...details, and Santen did not responds to inquiries. Santen Pharmaceutical Co. Ltd. (Tokyo:4536), Osaka, Japan R-Tech Ueno Ltd....

...Takeda said a regulatory setback for 3-D Matrix Ltd. (JASDAQ:7777) and a clinical setback for R-Tech Ueno Ltd....

...of Japan, Korea, Taiwan and China under an amended 2009 deal (see BioCentury, March 2). R-Tech Ueno Ltd....

...commercialize Rescula worldwide outside of Japan, Korea, Taiwan and China under an amended 2009 deal. R-Tech Ueno Ltd....

...from R-Tech to develop and commercialize Rescula worldwide outside of Japan, Korea, Taiwan and China. R-Tech Ueno Ltd....

...Japan granted Orphan Drug designation to unoprostone isopropyl from R-Tech Ueno to treat retinitis pigmentosa (RP). The...
...commercialize Rescula worldwide outside of Japan, Korea, Taiwan and China (see BioCentury, March 25, 2013). R-Tech Ueno Ltd....